

Azathioprine

Dr. Andrew Mackin, Mississippi State University

Azathioprine has been used as an immunosuppressive agent in dogs for over 50 years. The drug was initially primarily used in studies that utilized dogs as a model for investigations of organ transplantation and the effects of immunosuppression on various body systems. Within a few years, azathioprine was also being used to treat naturally-occurring diseases in dogs. Despite almost half a century of cumulative clinical and research experience on the use of azathioprine in dogs, however, there have been remarkably few studies that actually elucidate the precise effects that azathioprine has on the canine immune system (Ogilvie; Rinkardt; Harkin). Most of our understanding of the mechanism of action of azathioprine in dogs is extrapolated from work in other species.

Azathioprine is a prodrug for the active metabolite 6-mercaptopurine, and the primary mechanism of action was long believed to be inhibition of the synthesis of the purines adenine and guanine by blockage of enzymes such as amidophosphoribosyltransferase, with resultant production of nonfunctional nucleic acid strands. Disruption of purine synthesis inhibits DNA and RNA synthesis, thereby inhibiting the proliferation of fast-growing cells such as lymphocytes. In the past few decades, however, multiple other mechanisms of action mediated by various azathioprine metabolites have been proposed, including blockage of T cell activation and stimulation of T cell apoptosis. Azathioprine has long been reported to be more effective against T cell function than B cell function, although strong evidence supporting this is lacking (Dowling).

One of the key enzymes involved in azathioprine metabolism and inactivation is thiopurine methyltransferase (TPMT). Individual human patients (about one in 300 people) inherit a marked deficiency in the TPMT enzyme that renders them highly susceptible to azathioprine toxicity, particularly life-threatening bone marrow suppression. Interestingly, cats have also been shown to have a marked deficiency in TPMT enzyme activity (Foster), which may explain why azathioprine causes marked myelosuppression in cats at standard canine doses (Beale). Although the use of azathioprine at a very reduced dose rates has previously been published in cats, given the narrow margin for safety it is probably wisest to recommend that azathioprine never be used in cats at any dose, especially considering the availability of other immunosuppressive agents that appear to be much safer in cats, such as chlorambucil and cyclosporine. Although TPMT expression in dogs is widely variable, severe deficiencies in enzyme activity of the magnitude seen in cats and some people have not been commonly reported, and TPMT deficiency does not appear to be associated with the severe drug toxicities sometimes seen in dogs (Kidd; Rodriguez).

The standard azathioprine starting dose in dogs is 2 mg/kg orally once daily. This dose is usually well-tolerated and, although gastrointestinal side effects such as nausea, anorexia, vomiting and

diarrhea are occasionally reported, they are typically mild and self-limiting. Although, in dogs, marked myelosuppression is uncommon, chronic azathioprine usage almost invariably causes a mild to moderate poorly regenerative anemia. Since anemia is an expected outcome in dogs receiving azathioprine, and is typically very well tolerated (that is, sub-clinical), mild to moderate anemia alone should not be mistaken as evidence of either drug overdose or treatment failure. Uncommonly, azathioprine can also cause profound myelosuppression or severe hepatotoxicity in dogs (Rinkardt; Favrot). Marked myelosuppression and hepatotoxicity appear to be idiosyncratic non-dose-dependent drug reactions (Type B reactions), and are typically reversible if the problem is recognized early enough and azathioprine is discontinued (Houston; Rinkardt). Complete blood counts and serum biochemistry panels (especially ALT) should therefore be monitored regularly during initial azathioprine therapy. Several individual case reports have also reported pancreatitis in dogs receiving azathioprine, but cause and effect has not been established (Houston; Moriello).

Azathioprine has, over the years, become well-established as an ‘add on’ immunosuppressive agent to be considered for the treatment of many different immune-mediated and inflammatory conditions when glucocorticoids alone are ineffective or poorly tolerated, including immune-mediated hemolytic anemia (Burgess; Grundy; Weinkle; Pieke), immune-mediated thrombocytopenia, inflammatory bowel disease (Dandrieux), chronic hepatitis, glomerulonephritis, immune-mediated polyarthritis, myasthenia gravis (Dewey), non-infectious meningoencephalitis (Wong), immune-mediated skin diseases (Mueller; Rosenkrantz), and anal furunculosis (Harkin). Despite decades of azathioprine usage, evidence supporting immunosuppressive efficacy for many of these common diseases is remarkably limited. Interestingly, because (despite a relative paucity of evidence) azathioprine has commonly been recommended as the standard immunosuppressive drug of choice for many conditions, the efficacy of newer drugs for the treatment of these conditions is sometimes compared to a parallel group receiving azathioprine (Dandrieux; Wang). One perceived ‘limitation’ of azathioprine compared to other immunosuppressive agents, that it can take many weeks or even months to exert its effects, is based on limited and dated data derived predominantly in humans. In my experience, azathioprine in a clinical setting exerts its immunosuppressive effects in dogs about as rapidly as most other comparable agents (Dowling).

Compared to most other immunosuppressive agents, azathioprine is relatively inexpensive, which is an important consideration with long-term immunosuppressive therapy, especially in large dogs. While the proprietary product (Imuran® or Azasan®) typically still costs over \$5 per 50 mg tablet, the generic equivalent can be obtained for less than \$1 a tablet. The smallest tablet size is 50 mg (although tablet scoring permits a 25 mg dose), which can present dosing problems in small (under 20 lb) dogs.

- Beale K, Altman D, Clemmons R, Bolon B. Systemic toxicosis associated with azathioprine administration in domestic cats. *American Journal of Veterinary Research*. July 1992;53(7):1236-1240.
- Burgess K, Moore A, Rand W, Cotter S. Treatment of immune-mediated hemolytic anemia in dogs with cyclophosphamide. *Journal of Veterinary Internal Medicine*. July 2000;14(4):456-462.
- Dandrieux J, Noble P, Scase T, Cripps P, German A. Comparison of a chlorambucil-prednisolone combination with an azathioprine-prednisolone combination for treatment of chronic enteropathy with concurrent protein-losing enteropathy in dogs: 27 cases (2007-2010). *Journal of the American Veterinary Medical Association*. June 15, 2013;242(12):1705-1714.
- Dewey C, Coates J, Ducoté J, Meeks J, Fradkin J. Azathioprine therapy for acquired myasthenia gravis in five dogs. *Journal of the American Animal Hospital Association*. September 1999;35(5):396-402.
- Dowling P. Immunosuppressive drug therapy. *Canadian Veterinary Journal*. December 1995;36(12):781-783.
- Favrot C, Reichmuth P, Olivry T. Treatment of canine atopic dermatitis with azathioprine: a pilot study. *The Veterinary Record*. April 14, 2007;160(15):520-521.
- Foster A, Shaw S, Duley J, Shobowale-Bakre E, Harbour D. Demonstration of thiopurine methyltransferase activity in the erythrocytes of cats. *Journal of Veterinary Internal Medicine*. 2000;14(5):552-554.
- Grundy S, Barton C. Influence of drug treatment on survival of dogs with immune-mediated hemolytic anemia: 88 cases (1989-1999). *Journal of the American Veterinary Medical Association*. February 15, 2001;218(4):543-546.
- Harkin K, Phillips D, Wilkerson M. Evaluation of azathioprine on lesion severity and lymphocyte blastogenesis in dogs with perianal fistulas. *Journal of the American Animal Hospital Association*. January 2007;43(1):21-26.
- Houston D, Taylor J. Acute pancreatitis and bone marrow suppression in a dog given azathioprine. *The Canadian Veterinary Journal*. August 1991;32(8):496-497.
- Kidd L, Salavaggione O, Szumlanski C, Miller J, Weinshilboum R, Trepanier L. Thiopurine methyltransferase activity in red blood cells of dogs. *Journal of Veterinary Internal Medicine*. 2004;18(2):214-218
- Moriello K, Bowen D, Meyer D. Acute pancreatitis in two dogs given azathioprine and prednisone. *Journal of the American Veterinary Medical Association*. September 15, 1987;191(6):695-696.
- Mueller R, Krebs I, Power H, Fieseler K. Pemphigus foliaceus in 91 dogs. *Journal of the American Animal Hospital Association*. May 2006;42(3):189-196.
- Ogilvie G, Felsburg P, Harris C. Short-term effect of cyclophosphamide and azathioprine on selected aspects of the canine blastogenic response. *Veterinary Immunology and Immunopathology*. March 1988;18(2):119-127.

- Piek C, Junius G, Dekker A, Schrauwen E, Slappendel R, Teske E. Idiopathic immune-mediated hemolytic anemia: Treatment outcome and prognostic factors in 149 dogs. *Journal of Veterinary Internal Medicine*. March 2008;22(2):366-373.
- Piek C, van Spil W, Junius G, Dekker A. Lack of evidence of a beneficial effect of azathioprine in dogs treated with prednisolone for idiopathic immune-mediated hemolytic anemia: A retrospective cohort study. *BMC Veterinary Research*. April 13, 2011;7:15.
- Rinkardt N, Kruth S, Kaushik A. The effects of prednisone and azathioprine on circulating immunoglobulin levels and lymphocyte subpopulations in normal dogs. *Canadian Journal of Veterinary Research*. January 1999;63(1):18-24.
- Rinkardt N, Kruth S. Azathioprine-induced bone marrow toxicity in four dogs. *The Canadian Veterinary Journal*. October 1996;37(10):612-613.
- Rodriguez D, Mackin A, McLeod H, et al. Relationship between red blood cell thiopurine methyltransferase activity and myelotoxicity in dogs receiving azathioprine. *Journal of Veterinary Internal Medicine*. 2004;18(3):339-345.
- Rosenkrantz W. Pemphigus: Current therapy. *Veterinary Dermatology*. April 2004;15(2):90-98.
- Wang A, Creevy K, Smith J. Treatment of canine idiopathic immune-mediated haemolytic anaemia with mycophenolate mofetil and glucocorticoids: 30 cases (2007 to 2011). *Journal of Small Animal Practice*. August 2013;54(8):399-404.
- Weinkle T, Center S, Randolph J, Warner K, Barr S, Erb H. Evaluation of prognostic factors, survival rates, and treatment protocols for immune-mediated hemolytic anemia in dogs: 151 cases (1993-2002). *Journal of the American Veterinary Medical Association*. June 1, 2005;226(11):1869-1880.
- Wong M, Hopkins A, Meeks J, Clarke J. Evaluation of treatment with a combination of azathioprine and prednisone in dogs with meningoencephalomyelitis of undetermined etiology: 40 cases (2000-2007). *Journal of the American Veterinary Medical Association*. October 15, 2010;237(8):929-935.